Edgewise Therapeutics annual stock-based compensation
2020
2021
2022
2023
2024
2025
Edgewise Therapeutics Stock-Based Compensation Growth & History (EWTX)
Edgewise Therapeutics's stock-based compensation was $34.8M for fiscal 2025.
View full Edgewise Therapeutics company overviewEdgewise Therapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $34.8M | $10.0M | +40.63% |
| 2024 | 2024-12-31 | $24.7M | $7.2M | +40.73% |
| 2023 | 2023-12-31 | $17.6M | $6.6M | +60.75% |
| 2022 | 2022-12-31 | $10.9M | $6.5M | +148.05% |
| 2021 | 2021-12-31 | $4.4M | $4.0M | +1144.07% |
| 2020 | 2020-12-31 | $354,000 | — | — |
Edgewise Therapeutics quarterly stock-based compensation
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $9.4M | $1.6M | +21.07% |
| Q1 2026 | 2026-03-31 | $8.7M | −$344,000 | −3.80% |
| Q4 2025 | 2025-12-31 | $9.9M | $2.1M | +27.63% |
| Q3 2025 | 2025-09-30 | $8.1M | $1.2M | +17.51% |
| Q2 2025 | 2025-06-30 | $7.7M | $2.5M | +48.03% |
| Q1 2025 | 2025-03-31 | $9.1M | $4.2M | +85.98% |
| Q4 2024 | 2024-12-31 | $7.7M | $2.6M | +50.15% |
| Q3 2024 | 2024-09-30 | $6.9M | $2.3M | +50.91% |
| Q2 2024 | 2024-06-30 | $5.2M | $1.2M | +30.24% |
| Q1 2024 | 2024-03-31 | $4.9M | $1.0M | +26.95% |
| Q4 2023 | 2023-12-31 | $5.2M | $1.4M | +37.93% |
| Q3 2023 | 2023-09-30 | $4.6M | $1.4M | +43.68% |
| Q2 2023 | 2023-06-30 | $4.0M | $2.0M | +96.91% |
| Q1 2023 | 2023-03-31 | $3.8M | $1.9M | +93.98% |
| Q4 2022 | 2022-12-31 | $3.7M | $1.9M | +99.47% |
| Q3 2022 | 2022-09-30 | $3.2M | $1.6M | +104.97% |
| Q2 2022 | 2022-06-30 | $2.0M | $1.4M | +196.51% |
| Q1 2022 | 2022-03-31 | $2.0M | $1.7M | +568.24% |
| Q4 2021 | 2021-12-31 | $1.9M | $1.7M | +885.79% |
| Q3 2021 | 2021-09-30 | $1.5M | $1.5M | +2111.43% |
| Q2 2021 | 2021-06-30 | $687,000 | $638,000 | +1302.04% |
| Q1 2021 | 2021-03-31 | $296,000 | $251,000 | +557.78% |
| Q4 2020 | 2020-12-31 | $190,000 | — | — |
| Q3 2020 | 2020-09-30 | $70,000 | — | — |
| Q2 2020 | 2020-06-30 | $49,000 | — | — |
| Q1 2020 | 2020-03-31 | $45,000 | — | — |
Edgewise Therapeutics stock-based compensation trends
Over the last five fiscal years, Edgewise Therapeutics's stock-based compensation increased from $354,000 to $34.8M, a change of $34.4M. The latest reported quarter, Q2 2026, shows $9.4M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Edgewise Therapeutics source filings ↗